Top Markets
Coin of the day
DICE Therapeutics, Inc. DICE Therapeutics, Inc.

DICE Therapeutics, Inc.

DICE
Rank in Stocks #9048
DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating... DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications. Furthermore, DICE is advancing other oral treatment options, including therapies aimed at the α4β7 integrin for the management of inflammatory bowel diseases, and compounds targeting the αVβ1/αVβ6 integrin to treat idiopathic pulmonary fibrosis. Beyond these areas, the company also dedicates efforts to immuno-oncology, specifically developing antibody-based therapeutics. Established in 2013, DICE Therapeutics is headquartered in South San Francisco, California.
Share Price
$47.55
Last synced: 2023-08-18
Market Cap
$1.10B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade DICE Therapeutics, Inc. (DICE)

Category

Stock price history for DICE Therapeutics, Inc. (DICE)
Highest end of day price: $47.49 on 2023-08-01

Lowest end of day price: $34.06 on 2021-09-01
Stock price history of DICE Therapeutics, Inc. from 2021 to 2026
Annual Stock Price Performance
Year Performance
2023 45.03%
2022 26.23%
2021 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH